U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06793943) titled 'A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults' on Jan. 21.
Brief Summary: The main aim of this study is to find out how zasocitinib (TAK-279) interacts with other medicines taken by mouth (orally). This will be examined by how the body processes medicines, which is called pharmacokinetics or PK. In this study, other medicines that will be administered together with zasocitinib include a contraceptive (levonorgestrel (LNG) and ethinyl estradiol [EE]), a medicine for diabetes (metformin), a medicine used for heart problems (digoxin), and a medicine that blocks the production of stomach acid (es...